• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP NEWS SCAN: Zika treatment trial; H9N2 illness in China

Shiloh

Editor, Senior Moderator
Source: http://www.cidrap.umn.edu/news-perspective/2018/08/news-scan-aug-01-2018


News Scan for Aug 01, 2018
Zika treatment trial; H9N2 illness in China
Filed Under:
Zika; Avian Influenza (Bird Flu)


[h=3]Zika immune globulin treatment trial launches[/h] Yesterday Emergent BioSolutions announced the start of a phase 1 clinical trial for ZIKV-IG, the company's anti-Zika virus immune globulin. The double-blind, randomized, and placebo-controlled clinical study will enroll about 30 healthy volunteers at a single site.
The US Food and Drug Administration (FDA) granted fast-track designation to ZIKA IG in December of 2017. ZIKA-IG is a purified human immunoglobulin which contains Zika-neutralizing antibodies. Emergent BioSolutions has applied similar immunoglobulin and antibody technology to products aimed at treating anthrax bacteria and vaccinia virus.
"Our program, initiated in 2017, seeks to accelerate development of a Zika-specific immune globulin that leverages our proven platform technology, four decades of patient experience with hyperimmunes, and core competencies in advanced development and manufacturing," said Laura Saward, PhD, senior vice president and antibody therapeutics business unit head at Emergent BioSolutions in a press release.
Jul 31 Emergent BioSolutions press release

[h=3]Third case of H9N2 reported in China[/h] A woman from Shenzhen is the third human case of H9N2 avian influenza recorded in China this year, according to Avian Flu Diary (AFD), an infectious disease news blog. The blog published a translated notice of the case from Macao's Government Information Bureau.
Officials in Guandong Province confirmed the case in a 24-year-old woman who was hospitalized on Jul 23 after symptoms began 2 days earlier.
There is no mention of poultry exposure in the case notice, but most cases of H9N2 occur after human-bird contact, and most resolve after mild illness. The two cases reported earlier this year involved a child from Guangdong province and a woman Beijing.
Only three countries, China, Pakistan, and Egypt, have reported human cases of H9N2 in the past 20 years.
Aug 1 AFD post
Mar 19 CIDRAP News scan "Three H9N2 infections reported in China"
 
Back
Top Bottom